Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Vaxcyte, Inc. PCVX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
52/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$83.00
+32.2%

Vaxcyte, Inc. (PCVX) is a Biotechnology company in the Healthcare sector, currently trading at $62.76. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is PCVX = $83 (+32.2% upside).

Valuation: PCVX trades at a trailing Price-to-Earnings (P/E) of -10.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 6.38.

Net income is $767M (loss), growing at -49.5%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $229M against $2.7B equity (Debt-to-Equity (D/E) ratio 0.09, conservative). Current ratio is 7.91 (strong liquidity). Debt-to-assets is 7.5%. Total assets: $3.0B.

Analyst outlook: 11 / 11 analysts rate PCVX as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 58/100 (Partial), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 40/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$83.00
▲ 32.25% Upside
Average Price Target
Based on 11 Wall Street analysts offering 12-month price targets for Vaxcyte, Inc., the average price target is $83.00, with a high forecast of $89.00, and a low forecast of $77.00.
Highest Price Target
$89.00
Average Price Target
$83.00
Lowest Price Target
$77.00

PCVX SharesGrow Score Overview

63/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 58/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — PCVX

~
VALUE Partial
58/100
PCVX trades at a trailing Price-to-Earnings (P/E) of -10.7 (S&P 500 average ~25). Forward PEG 6.38 — overvalued. Trailing PEG 0.76. Analyst consensus target is $83, implying +32.2% from the current price $63. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
PCVX: +0%/yr revenue is, -49.5%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet PCVX: Debt-to-Equity (D/E) ratio 0.09 (conservative), Current ratio is 7.91 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
PCVX: Gross margin is 0% (+0 pp trend), $9B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 11 / 11 analysts rate PCVX as buy (100%). Analyst consensus target is $83 (+32.2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range27.66-65
Volume982.63K
Avg Volume (30D)1.44M
Market Cap$9.03B
Beta (1Y)1.39
Share Statistics
EPS (TTM)-5.63
Shares Outstanding$136.09M
IPO Date2020-06-12
Employees414
CEOGrant E. Pickering
Financial Highlights & Ratios
EBITDA$-741.77M
Net Income$-766.63M
Operating Income$-923.68M
Total Cash$1.56B
Total Debt$228.84M
Net Debt$54.88M
Total Assets$3.05B
Price / Earnings (P/E)-11.1
Analyst Forecast
1Y Price Target$83.00
Target High$89.00
Target Low$77.00
Upside+32.2%
Rating ConsensusBuy
Analysts Covering11
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS92243G1085

Price Chart

Track all markets on TradingView
PCVX
Vaxcyte, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
27.66 52WK RANGE 65.00

People Also View

BMRN
BMRN
BioMarin Pharmaceutical Inc.
$55.47
+1.08%
 TECH
TECH
Bio-Techne Corporation
$58.66
+1.96%
 NUVL
NUVL
Nuvalent, Inc.
$105.02
+1.28%
 MRUS
MRUS
Merus N.V.
$90.00
+0.00%
 ACLX
ACLX
Arcellx, Inc.
$114.89
+0.02%
 APLS
APLS
Apellis Pharmaceuticals, Inc.
$40.85
+0.02%
 AKRO
AKRO
Akero Therapeutics, Inc.
$54.65
+0.00%
 TVTX
TVTX
Travere Therapeutics, Inc.
$42.13
+37.23%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message